Research – Fragile X syndrome
From September / October 2018 Zynerba Pharmaceuticals is running a clinical trial in Australia in boys and girls with Fragile X syndrome, aged between 3 and 17. The trial sites are in Melbourne, Brisbane and Sydney. This a followup to a trial run in Australia in 2017 of a transdermal CBD gel.
The following is provided for information only.
From the Zynerba Pharmaceuticals website:
“ZYN002 is the first and only pharmaceutically-produced CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is being developed for patients suffering from Fragile X syndrome (FXS) and certain refractory epilepsies including developmental and epileptic encephalopathies (DEE). The FDA has granted Zynerba Orphan Drug designation for the use of CBD as treatment of patients with FXS.”
The flyer for the trial has contact details for each of the trial sites in Australia:
Page updated 23 October 2018
Screening for Fragile X
Fragile X Association of Australia strongly supports Fragile X genetic testing and screening for families for the purpose of identifying people:
- with Fragile X genetic related disorders:
- at risk of developing Fragile X-associated disorders, and/or
- at risk of having a child with a Fragile X-associated disorder.
Testing and screening approaches should be based on comprehensive research and families provided with appropriate counselling and clinical management.